You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
愛美客(300896.SZ)2020年度淨利潤升43.93%至4.4億元 擬10轉8派35元
格隆匯 02-08 21:44

格隆匯 2 月 8日丨愛美客(300896.SZ)發佈2020年年度報吿,實現營業收入7.09億元,同比增長27.18%;歸屬於上市公司股東的淨利潤4.40億元,同比增長43.93%;歸屬於上市公司股東的扣除非經常性損益的淨利潤4.24億元,同比增長42.95%;基本每股收益4.51元,擬每10股派發現金紅利35元(含税),以資本公積金向全體股東每10股轉增8股。經營活動產生的現金流量淨額4.26億元,同比增長37.44%。

報吿期內,已成功實現注射類透明質酸鈉系列產品及聚對二氧環己酮面部埋植線的產業化,並建立了醫用幾丁糖、聚乳酸等生物醫用材料的產品技術轉化平台。

公司目前的主要產品為:III類醫療器械繫列注射用透明質酸鈉產品、面部埋植線產品、衍生的品牌矩陣伴侶型化粧品。在醫療美容領域,公司擁有豐富的醫美III類醫療器械產品線,具有產品佈局差異化的競爭優勢。公司以持續賦能醫療美容醫生技術培訓為基礎,推動行業生態的良性發展,為客户和消費者帶來便捷舒適、安全有效的良好體驗。

公司系列透明質酸鈉產品分為凝膠類和溶液類注射產品。凝膠類產品:醫用含聚乙烯醇凝膠微球的透明質酸鈉-羥丙基甲基纖維素凝膠,注射用修飾透明質酸鈉凝膠和醫用透明質酸-羥丙基甲基纖維素凝膠。溶液類產品:注射用透明質酸鈉複合溶液,醫用羥丙基甲基纖維-透明質酸鈉溶液;此外,公司已經上市的醫療器械產品還有聚對二氧環己酮面部埋植線。

此外,公司還在不斷研發其他醫療美容領域的醫療產品,包括含聚乳酸用於皮膚功能性治療的注射產品,注射用A型肉毒毒素藥品,用於慢性體重管理的注射用基因重組蛋白藥物等。豐富的在研產品佈局,為公司未來持續快速發展提供了有力支撐。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account